Gland Pharma Board of Directors
Get the latest insights into the leadership at Gland Pharma. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Srinivas Sadu | Executive Chairman |
| Mr. Wenjie Zhang | Non Exe.Non Ind.Director |
| Mr. Wei Huang | Non Exe.Non Ind.Director |
| Dr. Jia Ai (Allen) Zhang | Non Exe.Non Ind.Director |
| Mr. Essaji Goolam Vahanvati | Independent Director |
| Mr. Udo Johannes Vetter | Independent Director |
| Mr. Satyanarayana Murthy Chavali | Independent Director |
| Ms. Naina Lal Kidwai | Independent Director |
Gland Pharma Share price
GLAND
1821.7
18.80 (-1.02%)NSE
BSE
Last updated on 20 Feb, 2026 | 15:46 IST
BUYSELL
Today's High
1838.10
Today's Low
1813.50
52 Week Low
1277.80
52 Week High
2131.00
Free Demat with Zero AMC*
Gland Pharma FAQs
The board at Gland Pharma consists of experienced professionals, including Mr. Srinivas Sadu , Mr. Wenjie Zhang , and others, overseeing the company’s strategic and corporate governance.
Directors at Gland Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Srinivas Sadu is the current chairman at Gland Pharma.
Executive directors at Gland Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Gland Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Gland Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.
